CLINICAL CASE

Addison’s disease and ACTH-producing pituitary microadenoma

S.S. Ortega*, Y.H. Aguiar, P.P. Marrero, S.M. Casas

Hospital General de Gran Canaria Dr. Negrín, Barranco de la Ballena s/n, 35010 Las Palmas de Gran Canaria, Spain

Received 23 February 2015; accepted 8 August 2015
Available online 23 October 2015

Keywords
Nelson’s syndrome; ACTH; Addison’s disease; Autoimmune adrenalitis

Abstract
A 28-year-old man diagnosed with primary adrenal insufficiency (Addison’s disease) in 2002. Following diagnosis, replacement therapy with hydrocortisone and fludrocortisone was indicated. Hydrocortisone replacement therapy was unsuccessful, and increased ACTH levels as high as 996 pg/dl were observed on outpatient follow-up. A pituitary MRI revealed a pituitary microadenoma. These findings raised three possibilities: (1) treatment is insufficient; (2) there is no relationship between Addison’s disease and pituitary microadenoma; and (3) the microadenoma is similar to Nelson’s syndrome. This latter is the most satisfactory explanation of this patient’s clinical picture.

© 2015 Sociedad Médica del Hospital General de México. Published by Masson Doyma México S.A. All rights reserved.

Enfermedad de Addison y microadenoma hipofisario productor de ACTH

Resumen
Un varón de 28 años fue diagnosticado de insuficiencia suprarrenal primaria autoinmune (enfermedad de Addison) en el año 2002. Tras ello, se indica tratamiento sustitutivo con hidrocortisona y fludrocortisona. En el seguimiento ambulatorio se objetivó un aumento de los niveles de ACTH, llegando a 996 pg/dl, con tratamiento sustitutivo con hidrocortisona que no logra suprimir la ACTH. Por ello se realiza RMN de hipófisis donde se objetiva un microadenoma hipofisario. Ante estos hallazgos se plantearon tres posibilidades: 1.- El tratamiento es insuficiente; 2.- No existe relación entre la enfermedad de Addison y el microadenoma hipofisario; 3.- El microadenoma se considera una situación clínica similar al síndrome de Nelson. Esta última respuesta es la que da una explicación más satisfactoria al cuadro clínico de este paciente.

© 2015 Sociedad Médica del Hospital General de México. Publicado por Masson Doyma México S.A. Todos los derechos reservados.

* Corresponding author at: Urbanización El Arco, 16, La Atalaya, 35307 Santa Brigida, Las Palmas, Spain.
E-mail address: drsuarez@hotmail.com (S.S. Ortega).

http://dx.doi.org/10.1016/j.hgmx.2015.08.007
0185-1063/© 2015 Sociedad Médica del Hospital General de México. Published by Masson Doyma México S.A. All rights reserved.
Introduction

Addison’s disease is characterised by failure of the adrenal glands to produce sufficient steroid hormones, the most common aetiology being autoimmune adrenalitis and tuberculosis. This causes the classic signs of suprarenal insufficiency, along with the melanoderma typical of increased adrenocorticotropic hormone (ACTH) secretion.\(^1,2\) ACTH overproduction in response to decreased cortisol levels can also be caused by an autonomously functioning pituitary adenoma, as seen in Nelson’s syndrome.\(^3,4\) The ACTH increase seen in Addison’s disease could also be due to primary pituitary ACTH hypersecretion unrelated to cortisolemia,\(^5\) or to both of the foregoing cases. We present the case of a pituitary microadenoma in a patient with Addison’s disease that could be interpreted as either Nelson’s syndrome or primary pituitary ACTH hypersecretion coexisting with Addison’s disease. The gradual increase in ACTH levels despite appropriate replacement therapy with hydrocortisone would seem to bear out the latter hypothesis. This clinical situation could also be explained by ACTH hypersecretion secondary to adrenal dysfunction that eventually becomes autonomous, as in tertiary hyperparathyroidism in kidney failure.\(^6\)

Case study

A 28-year-old man was admitted to our hospital in 2002 for periodic paralysis, anorexia, weight loss of 8 kg in the previous 12 months, vomiting and general malaise. On physical examination, he presented hyperpigmentation of the palms of the hands, oral mucosa, and axillary and inguinal folds. Arterial pressure was 90/60 mmHg, heart rate was 96 bpm, axillary temperature was 37 °C, weight 62 kg and height 1.69 cm. Emergency laboratory tests showed hyponatraemia (128 mEq/l) and mild hyperpotassaemia (6.1 mEq/l), slightly elevated BUN and normal creatinine. Once ionic changes had been normalised, we measured basal cortisol (less than 1 mcg/dl) and ACTH levels (336 pg/ml, normal levels up to 50 pg/ml). This was followed by a prolonged ACTH stimulation test, with no elevation of cortisolaemia. We started replacement treatment with 30 mg hydrocortisone and 0.1 mg fludrocortisone daily, with outpatient follow-up. Antiadrenal antibody levels were >1/20 (normal, absent). On follow-up, ACTH levels remained elevated and did not respond to replacement therapy, so this was increased to 40 mg hydrocortisone daily. ACTH was measured every 2 years between 2004 and 2014, showing levels of 405, 438, 710, 782, 489 and 996 pg/ml. Prolactin, FSH-LH, TSH and GGH levels were normal. Over the prolonged follow-up period, the patient has adhered strictly to the therapeutic regimen (Morisky Green test), and has had no intercurrent disease or need for hospitalisation. On the basis of ACTH levels, we decided to perform a targeted MRI examination of the pituitary region, which revealed a cold lesion measuring 2.5 mm, compatible with a pituitary microadenoma (Fig. 1). The long clinical evolution, with normal findings on serial campimetry and imaging studies (chest X-ray and abdominal ultrasound), all but rules out the coexistence of ectopic ACTH secretion.

Discussion

Our patient meets the criteria for ACTH-secreting pituitary adenoma, with no clinical signs of a space-occupying lesion. As the most characteristic sign of increased ACTH is melanoderma, we decided to perform periodic follow-up of ACTH levels with laboratory tests and MRI of the pituitary gland. However, other non-specific signs associated with this case could benefit from some strategies reported in the literature.\(^7\)

Nelson’s syndrome, the enlargement of an autonomous ACTH-secreting pituitary adenoma, is a typical clinical presentation following bilateral adrenalectomy for Cushing’s syndrome, and would explain the clinical picture following autoimmune adrenalitis in this case.\(^8\) The extended time lapse between onset of symptoms and diagnosis of Addison’s disease in this patient could have caused Nelson’s syndrome, as during this period ACTH secretion continued unchecked due to low cortisol levels.\(^9,10\) Although many

Figure 1  T1 weighted spin echo sequence with IV gadolinium in sagittal and coronal plane. Cold, 2.5 mm lesion located in the centre of the anterior pituitary. Compatible with microadenoma.
Addison’s disease and ACTH-producing pituitary microadenoma

authors suggest that this is not such a rare occurrence, a Medline search retrieved only 1 article specifically analysing this problem. For this reason, we have decided to adopt a wait-and-see, symptom-guided approach complemented by follow-up campimetry tests and imaging studies.\(^4\)

Another, albeit unlikely, hypothesis put forward to explain these symptoms is non-adrenal function-related pituitary ACTH hypersecretion, in which both processes would have developed independently.

Treatment strategies, in the absence of evidence of any other hormonal dysfunction other than ACTH, and no neurological symptoms, remain unclear.\(^6\) However, ACTH hypersecretion could improve with replacement therapies aimed at improving adrenal hormone homeostasis.\(^11\) This approach is similar to that taken in diabetes, where insulin is replaced by a basal-bolus regimen.

Conclusions

We present a case of Addison’s disease treated with replacement therapy that actually increased, rather than reduced, ACTH levels. Observing rising levels over time, we decided to perform MRI of the pituitary gland, which showed the presence of a microadenoma. Various hypotheses have been put forward to explain this phenomenon:

1. Conventional treatment is ineffective in inhibiting ACTH production.
2. The pituitary microadenoma is unrelated to Addison’s disease or any suprarenal dysfunction.
3. The microadenoma is caused by an autoimmune adrenali-

References